Don't want to wait in the phone queue? Contact us via SystmConnect. NO ACCOUNT NEEDED! Click here to get started...

Health Care First are accepting new patients. You can register online today, simply click here

icon

Research and Development

Message from Dr Khan lead research GP Health Care First

Message from Dr Khan, Lead Research GP at Health Care First.

It gives me great pride to introduce the work we are doing at Health Care First. Our vision has always been to lead from the front in medical research and service innovation. Over the past two years, we have made remarkable progress, bringing the latest advances in medical interventions closer to the doors of our patients.

What matters most is that these projects are not just about research—they are about transforming care, improving access, and making a difference in the everyday lives of our patients. We are proud of the impact we have achieved locally, and equally proud that our work is now influencing practice both nationally and internationally.

icon

HCF Research Unit 

We have also developed the Health Care First Research Unit, a dedicated hub for delivering high-quality research in primary care. This marks a major step forward in expanding our capability to support both academic and commercial trials within the community.

Our first commercial study, EASi-PROTKT, is now underway. This international Phase III trial is testing the combination of vicadrostat (BI 690517) and empagliflozin in people with type 2 diabetes, high blood pressure, and cardiovascular disease. The aim is to find out whether this combination can reduce the risk of cardiovascular events such as heart attacks, strokes, and heart failure. About 11,800 participants will be recruited worldwide, including around 236 in the UK, with follow-up lasting between 2.5 and 4.25 years.

By hosting EASi-PROTKT, we are not only contributing to an important international research effort but also ensuring that our patients gain access to the very latest therapies and innovations.

HCF Cardiology hcfcardiology.co.uk

The HCF Cardiology team is made up of committed professionals led by Dr Murad Khan, a General Practitioner with an Extended Role in Cardiology. Since 2001, we have been recognised for our innovation and our strength in bringing specialist cardiovascular care closer to patients in the community. Our focus is on improving cardiovascular risk prevention and advancing early detection of significant arrhythmias.

Over the past year, we have successfully delivered the Wakefield Palpitations Service, assessing more than 600 patients. Building on this success, we are now expanding to serve patients with Postural Orthostatic Tachycardia Syndrome (POTS). This represents a unique, first-of-its-kind primary care service for POTS in the UK.

Studies 

We have contributed to or are currently involved in the following studies and trials: 

  • Alabama Study – Conexus Healthcare (conexus-healthcare.org) 
  • SAFER – Screening for Atrial Fibrillation (cam.ac.uk) 
  • Embrace Study (embracevaccinestudy.com)
  • PROSPER – Personalised Care Planning for Older People with Frailty – Bradford Institute for Health Research (bradfordresearch.nhs.uk) 
  • SPECTRA – Identification of Suspected Severe Asthma in Adults (suspected-severe-asthma.co.uk)
  • The ERICA Trial
  • The PinPoint Test – West Yorkshire and Harrogate Cancer Alliance (wyhpartnership.co.uk)
  • RECORD – Reported Outcomes in COPD with Trixeo in Real World Practice (hra.nhs.uk) · Lean-DM (hra.nhs.uk)

Projects

  • COPD patient review completed in collaboration with AstraZeneca and Spirit
  • Asthma review (Sentinel) completed in collaboration with AstraZeneca and Interface
  • Oral nutritional support prescription review completed with Interface
  • COPD and atrial fibrillation project using Fibricheck – completed
  • Urine ACR project – second phase completed in 2022
  • Cardiology and CKD pilots – both completed, leading to the development of new, sustainable care pathways

Publications

1. RCGP Conference 2021 Deepak Balasubramanian, M Murad Khan Significant Risk Hidden in Plain Sight: Citalopram 40 mg & Prolonged Qtc in Primary Care

2. HRC Birmingham 2022 M Murad KHAN, S Childe Innovative primary care lead community palpitation management and investigation pathway for Wakefield district European Journal of Arrhythmia & Electrophysiology. 2022;8(Suppl. 1):abstr91

3. EHRA 2023 M Murad KHAN, S Childe Primary care lead community palpitation management and investigation pathway March 2023 DOI: 10.13140/RG.2.2.15498.64964

4. ESC 2023 M. Khan1, SE. Evens2, S. Childe1, C. Hickling1, L. Abbott1 – (1) Health care first, Normanton, United Kingdom of Great Britain & Northern Ireland (2) Qompium NV, Hasselt, Belgium Remote heart rhythm assessment using smartphone-based photoplethysmography in primary care to detect undiagnosed atrial fibrillation in patients with chronic obstructive pulmonary disease

5. RCGP 2023 M. Khan1, SE. Evens2, S. Childe1, C. Hickling1, L. Abbott1 – (1) Health care first, Normanton, United Kingdom of Great Britain & Northern Ireland (2) Qompium NV, Hasselt, Belgium Remote heart rhythm assessment using smartphone-based photoplethysmography in primary care to detect undiagnosed atrial fibrillation in patients with chronic obstructive pulmonary disease